Berlin-Chemie AG is a German pharmaceutical company based in Berlin, Germany. It is part of the Menarini Group.

IndustryPharmaceutical industry
Key people
Luca Lastrucci (Chairman of the Executive Board)
Edward Szybowski
Christian Matschke
Attilio Sebastio
Christiane von der Eltz
Ivan Bergstein
Revenue1.5 billion EUR (2021)[1]
Number of employees
5,000 (2021)[1]

History Edit

Berlin-Chemie considers the establishment of a plant for the laboratory preparations of the Chemical factory of Kahlbaum in Berlin-Adlershof in 1890, as its origin. The first factory located in the former administrative district of Treptow, Berlin-Adlershof.[2] In 1927 after the merger with Schering AG employees began the development of drugs. When the state-owned companies were privatized or dissolved after the political turnaround, the Italian group Menarini took over the factory in Berlin in 1992, including the product name, and thus immediately found a larger sales market in Eastern Europe.[3]

Products Edit

In February 2013, Berlin-Chemie took over the Priligy brand, a drug against premature ejaculation. Since mid-2013, there has been a media campaign on the internet and through posters on the subject of premature ejaculation, which many physicians are critical of. According to the imprint of the website in question, Later, this is a media contribution by Berlin-Chemie AG.[4]

Since 2015, Berlin-Chemie has been able to manufacture and sell anti-cancer drugs through a license agreement with the Japanese drug manufacturer Chugai.[5]

The production of infusion solutions was discontinued in 2019.

References Edit

  1. ^ a b Berlin Chemie AG
  2. ^ "Berliner Adreßbuch. Issue". Retrieved October 12, 2019.
  3. ^ "Berliner Adreßbuch. Issue". Retrieved October 12, 2019.
  4. ^ Kuhrt, Nicola (2013-07-17). "Vorzeitiger Samenerguss: Pharmakonzern erfindet Massenleiden". Der Spiegel (in German). ISSN 2195-1349. Retrieved 2022-02-01.
  5. ^ &NA (March 2005). "Chiron Corporation's license to manufacture Fluvirin [influenza virus vaccine] has been reinstated". Inpharma Weekly. &NA (1478): 3. doi:10.2165/00128413-200514780-00005. ISSN 1173-8324. S2CID 195135382.

External links Edit